|
π
|
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
21 auth.
T. Chonghaile,
K. Sarosiek,
Thanh-Trang T. Vo,
J. Ryan,
Anupama Tammareddi,
V. Moore,
Jing Deng,
K. Anderson,
P. Richardson,
Y. Tai,
...
C. Mitsiades,
U. Matulonis,
R. Drapkin,
R. Stone,
D. DeAngelo,
D. McConkey,
S. Sallan,
L. Silverman,
M. Hirsch,
D. Carrasco,
A. Letai
|
9 |
2011 |
9
π
|
|
π
|
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.
10 auth.
S. Lim,
X. L. Chen,
Yangmi Lim,
Daniel A. Hanson,
Thanh-Trang T. Vo,
Kyle Howerton,
...
N. Larocque,
S. Fisher,
D. Schlaepfer,
D. IlicΜ
|
8 |
2008 |
8
π
|
|
π¦
|
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
9 auth.
Thanh-Trang T. Vo,
J. Ryan,
Ruben D Carrasco,
D. Neuberg,
Derrick J. Rossi,
R. Stone,
...
D. DeAngelo,
M. Frattini,
A. Letai
|
8 |
2012 |
8
π¦
|
|
π
|
Statins enhance efficacy of venetoclax in blood cancers
23 auth.
J. S. Lee,
A. Roberts,
D. Juarez,
Thanh-Trang T. Vo,
Shruti Bhatt,
Lee-or Herzog,
Sharmila Mallya,
Richard J. Bellin,
S. Agarwal,
A. Salem,
...
A. Salem,
T. Xu,
Jia Jia,
Lingxiao Li,
John R. Hanna,
M. Davids,
Angela G. Fleischman,
S. O'Brien,
L. Lam,
J. Leverson,
A. Letai,
J. Schatz,
D. Fruman
|
6 |
2018 |
6
π
|
|
π¦
|
BH3-only proteins and their effects on cancer.
Thanh-Trang T. Vo,
A. Letai
|
5 |
2010 |
5
π¦
|
|
π
|
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.
10 auth.
P. Bhola,
B. Mar,
R. C. Lindsley,
J. Ryan,
L. Hogdal,
Thanh-Trang T. Vo,
...
D. DeAngelo,
I. Galinsky,
B. Ebert,
A. Letai
|
5 |
2016 |
5
π
|
|
π¬
|
Synthesis of the C1-phosphonate analog of UDP-GlcNAc.
Robert Chang,
Thanh-Trang T. Vo,
N. Finney
|
5 |
2006 |
5
π¬
|
|
π
|
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
9 auth.
Brandon R. Beagle,
D. Nguyen,
Sharmila Mallya,
Sarah S. Tang,
Mengrou Lu,
Z. Zeng,
...
M. Konopleva,
Thanh-Trang T. Vo,
D. Fruman
|
5 |
2014 |
5
π
|
|
π¬
|
Targeting mTOR for the treatment of B cell malignancies.
J. S. Lee,
Thanh-Trang T. Vo,
D. Fruman
|
4 |
2016 |
4
π¬
|
|
π¬
|
MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
J. S. Lee,
Sarah S. Tang,
Veronica Ortiz,
Thanh-Trang T. Vo,
D. Fruman
|
4 |
2015 |
4
π¬
|
